Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2019 · 10-Q
Revenue$339.00K$339.00K+156.8% vs Q1 2018 Net Income-$20.95M-$20.95MN/M vs Q1 2018 EPS Diluted-$0.04-$0.04N/M vs Q1 2018 Operating Income-$7,766,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Margins · derivedOperating margin-2290.9%+4387.9 pt vs Q1 2018
Net margin-6178.8%+10143.2 pt vs Q1 2018
ended Mar 31, 2019 · filed May 10, 2019 · 40 d after period end